De-Risk Drug Discovery
First-of-its-kind AI trained on 1M+ outcome-linked papers that brings clarity to the earliest and riskiest stages of pharmaceutical research by forecasting probability of approval – years before clinical signals emerge.
De-risk pipeline
Make confident early-stage R&D and investments choices with drug discovery landscapes for 5,846 rare diseases featuring likelihood of approval percentiles.
Monitor opportunities
Continuous monitoring of emerging novel therapies with the highest approval potential, delivered as memorandums personalized to specific pipelines.
Repurpose drugs
Selecting and ranking successful opportunities for therapeutic repurposing by targets and mechanisms across more than 1 million drug discovery publications.
